新型免疫分析法精准定量醛固酮:克服低值不准确与肾功能不全干扰
研究系统评估了新型两步夹心化学发光免疫分析法(sCLIA)定量血浆醛固酮浓度的性能,并在中国七中心2696例样本中与竞争性化学发光免疫分析法(cCLIA)及液相色谱-串联质谱(LC-MS/MS)平行比较。sCLIA分析性能优异,与LC-MS/MS一致性优于cCLIA,尤其在低醛固酮浓度(<110 ng/L)和肾功能减退(eGFR<60 mL/min/1.73 m2)受试者中。结论认为sCLIA结合了免疫分析实用性与LC-MS/MS准确性,适合大规模原发性醛固酮增多症筛查。
要点
- sCLIA批内不精密度<4.64%,与认证参考物质偏倚<5.71%。
- sCLIA报告范围30-100,000 ng/L,定量限30 ng/L,稀释能力≥50倍。
- 在低PAC(<110 ng/L)和eGFR<60 mL/min/1.73 m2者中sCLIA与LC-MS/MS一致性优于cCLIA。
核心结论
- 新型sCLIA分析性能优异,兼具免疫分析实用性与LC-MS/MS准确性,适合大规模原发性醛固酮增多症筛查。
研究设计与样本
- 多中心研究纳入中国七中心2696例样本,平行使用sCLIA、cCLIA和LC-MS/MS测定PAC。
- 系统验证sCLIA的精密度、正确度、线性范围和最大稀释倍数,并重点评估低醛固酮浓度和慢性肾脏病(CKD)患者中的性能。
主要发现
- sCLIA批内不精密度<4.64%,与认证参考物质偏倚<5.71%。
- sCLIA报告范围30-100,000 ng/L,定量限30 ng/L,稀释能力≥50倍。
- 与cCLIA相比,sCLIA与LC-MS/MS一致性更优,尤其在低PAC浓度(<110 ng/L)和eGFR<60 mL/min/1.73 m2的受试者中。
关键数值与推荐
- sCLIA批内不精密度<4.64%,与认证参考物质偏倚<5.71%。
- sCLIA报告范围30-100,000 ng/L,定量限30 ng/L,稀释能力≥50倍。
- 低PAC浓度定义为<110 ng/L;肾功能减退定义为eGFR<60 mL/min/1.73 m2。
临床怎么用
- sCLIA可用于临床大规模原发性醛固酮增多症筛查,尤其在低醛固酮浓度和肾功能减退患者中可减少cCLIA的过高估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Accurate quantification of aldosterone is critical for screening and diagnosing primary aldosteronism (PA). Current competitive chemiluminescence immunoassays (cCLIA) overestimate plasma aldosterone concentration (PAC) compared to liquid chromatography-tandem mass spectrometry (LC-MS/MS). However, LC-MS/MS is technically demanding and time-consuming, limiting its widespread clinical utility. Therefore, a novel two-step sandwich chemiluminescence immunoassay (sCLIA) for accurate quantification of PAC was systematically evaluated. METHODS: Precision, trueness, linear range, and maximum dilution factor of the new immunoassay were comprehensively validated. In a multicenter study involving 2,696 samples from seven Chinese centers, PAC measurements were performed in parallel using sCLIA, cCLIA, and LC-MS/MS. The study specifically focused on evaluating the assay's performance at low aldosterone concentrations and in patients with chronic kidney disease (CKD), investigating potential interference from renal impairment by comparing the consistency between immunoassays and LC-MS/MS results across different CKD stages. RESULTS: The sCLIA exhibited excellent analytical performance for PAC measurement, with intra-assay imprecision <4.64 % and bias <5.71 % against certificated reference materials. The assay exhibited a wide reportable range (30-100,000 ng/L) with a limit of quantification at 30 ng/L and dilution capability ≥50-fold. Compared to cCLIA, sCLIA showed superior agreement with LC-MS/MS, particularly at low PAC concentrations (<110 ng/L) and in subjects with reduced renal function (eGFR<60 mL/min/1.73 m2). CONCLUSIONS: This novel sCLIA method exhibited excellent analytical performance, combining the practical advantages of immunoassays with LC-MS/MS accuracy, thereby offering an ideal solution for large-scale primary aldosteronism screening in clinical practice.
引用
- Wang K, Cong H, Gao Z, et al. An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference. Clin Chem Lab Med. 2025. PMID: 40842291. doi:10.1515/cclm-2025-0743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。